Bristol-Myers, ImClone Partnership No Longer Threatened

02/28/2002 | Wall Street Journal, The

Bristol-Myers Squibb reportedly has abandoned its threat to break off its marketing partnership with ImClone. Fears over ImClone's cancer drug Erbitux were quelled, company officials said, after a successful meeting Tuesday between ImClone and the FDA. A source said Bristol-Myers still wants to renegotiate the partnership, but an ImClone spokesman said, "We intend to work under the existing terms."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA